How to Apply to Eisai

16 min read Last updated April 20, 2026 87 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Eisai Co., Ltd. (TSE: 4523) is a top-five Japanese pharma founded in 1941 and headquartered in Koishikawa, Bunkyo-ku, Tokyo, with approximately 10,000 employees globally and major sites in Tsukuba (Japan), Andover MA, Nutley NJ, and Hatfield (UK).
  • CEO Haruo Naito has led the company since 1988 — one of the longest CEO tenures in corporate Japan at 36+ years — and is personally identified with the 'hhc' (human health care) philosophy and the 1% patient-time rule, both of which interview panels test for genuinely, not ceremonially.
  • Leqembi (lecanemab) is the defining asset of the Naito era: FDA accelerated approval January 2023, traditional approval July 2023, first disease-modifying anti-amyloid antibody with proven cognitive-decline slowing in early Alzheimer's, co-developed and co-commercialized 50/50 with Biogen; the 2025 subcutaneous maintenance formulation approval extended the franchise, but the real-world commercial ramp is infrastructure-limited and honestly below early blockbuster models.
  • Lenvima (lenvatinib) is the current largest revenue contributor, discovered in-house at Tsukuba, approved across thyroid cancer, hepatocellular carcinoma, RCC (in combination with Keytruda), and endometrial carcinoma, and commercialized worldwide under a 2018 strategic collaboration with Merck (MSD outside the U.S.).
  • The business is organized around two therapeutic domains (Neurology and Oncology) plus Consumer Healthcare, and four regional pillars (Japan, Americas, EMEA, Asia including China and APAC); candidates should target a specific domain and region in their application rather than applying to 'Eisai' generically.
  • Japanese new-graduate (shinsotsu) hiring for Eisai Co., Ltd. in Tokyo runs through the cohort-tagged mypage on Mynavi and the Eisai recruiting site on the Keidanren calendar, requires SPI3 aptitude testing, a group discussion round, and multi-round interviews, and typically offers a new-graduate starting salary in the 6-10 million JPY annual cash range for experienced-hire tracks like R&D and around 4.5-6 million JPY for early-career generalist and MR tracks.
  • Eisai Inc. (Nutley NJ) is a legally and operationally distinct U.S. subsidiary running a U.S. biotech-pattern hiring process with U.S. pharma-market compensation; candidates offered an MSL, medical affairs, or launch role at Nutley receive U.S. biotech bands rather than Japan HQ bands and should not conflate the two.
  • JLPT N2 is a practical floor for any Japan-based HQ corporate role and N1 is the de facto bar for HQ R&D planning, corporate strategy, legal, and IR functions; English-only candidates should target Nutley, Hatfield, Andover, or designated global roles rather than Tokyo HQ.
  • The most common reasons candidates decline Eisai offers are (1) brand and pay gap versus Takeda, Astellas, Daiichi Sankyo, and Chugai for Japanese candidates who want maximum prestige or scale, and (2) concerns about pipeline depth beyond Leqembi and Lenvima and the open succession question given CEO Naito's 36-year tenure; candidates who value neurology focus, patient-centricity, and long-cycle stewardship over short-cycle stock performance thrive here.

About Eisai

Eisai Co., Ltd. (TSE: 4523) is one of Japan's top-five pharmaceutical companies and, among its domestic peers, the one most deeply and publicly identified with central-nervous-system disease, particularly Alzheimer's and related dementias. The company traces its modern founding to 1941, when Toyoji Naito established Nihon Eisai Co., Ltd. as a consolidation of earlier Naito family pharmaceutical ventures dating to 1936, and was renamed Eisai Co., Ltd. in 1955. The corporate name is derived from the classical characters for 'hygiene' and 'material,' reflecting a long-standing mission framing that the company continues to use today under the English banner 'human health care,' almost always rendered internally and externally as 'hhc' (lower case), which since 1992 has been the central corporate philosophy and appears on nearly every piece of public communication. Headquarters sits at Koishikawa 4-6-10 in Bunkyo Ward, Tokyo, adjacent to the University of Tokyo Hongo campus; the company also operates major R&D centers in Tsukuba (Japan), Andover (Massachusetts), and Hatfield (UK), plus manufacturing sites across Japan, Europe, Asia, and North America. Total headcount is approximately 10,000 employees group-wide, with roughly half based in Japan, making Eisai a mid-sized global pharma by headcount but a disproportionately influential player in neurology, oncology, and global-health drug access. The company is led by Representative Corporate Officer and CEO Haruo Naito, grandson of founder Toyoji Naito, who has held the chief executive role continuously since 1988, one of the longest CEO tenures in corporate Japan at more than 36 years. Naito-san is personally associated with the company's 'hhc' philosophy, with its explicit commitment to spending time with patients (the well-known '1% rule' asking employees to spend 1% of working time directly with patients and caregivers), and with the strategic bet that defined the last decade of Eisai: the all-in pursuit of disease-modifying Alzheimer's therapy. That bet paid off in January 2023 with the U.S. FDA accelerated approval and in July 2023 with traditional approval of Leqembi (lecanemab), the first fully approved anti-amyloid monoclonal antibody proven to slow cognitive decline in early Alzheimer's disease, developed under a 50/50 co-development and co-commercialization partnership with Biogen that has been in place since 2014. Leqembi is now approved in the U.S., Japan, China, South Korea, the EU (with restrictions), the UK, and a growing list of additional markets, and its subcutaneous maintenance formulation gained FDA approval in 2025. For Eisai, Leqembi is simultaneously a scientific milestone, the defining asset of the Naito era, and a commercial learning curve: the real-world launch has been slower and more infrastructure-dependent than the headline approval suggested, because Alzheimer's diagnosis requires amyloid PET or CSF biomarker confirmation, infusion center capacity, and MRI monitoring for ARIA (amyloid-related imaging abnormalities). Candidates should understand that Leqembi is both the company's crown jewel and an honest commercial ramp story rather than an overnight blockbuster; revenue has been meaningful and growing but not yet at the multi-billion-dollar annual run rate some early models assumed. The second pillar of the modern Eisai portfolio is Lenvima (lenvatinib), a multi-target tyrosine kinase inhibitor discovered in-house at the Tsukuba research center and approved across thyroid cancer, hepatocellular carcinoma, renal cell carcinoma (in combination with Merck's Keytruda), and endometrial carcinoma. Lenvima is commercialized worldwide under a strategic collaboration with Merck & Co. (Merck KGaA's U.S. subsidiary, known as MSD outside the U.S.) signed in 2018; Eisai retains booking and manufacturing responsibility while sharing profits with Merck. Lenvima remains the largest single revenue contributor and is the reason candidates applying into oncology commercial, medical affairs, or global brand roles will spend significant time on combination strategy with Keytruda. Beyond Leqembi and Lenvima, Eisai's legacy portfolio includes Fycompa (perampanel) for epilepsy, Dayvigo (lemborexant) for insomnia, Halaven (eribulin) for metastatic breast cancer, the long-running Aricept (donepezil) franchise that historically defined the company's Alzheimer's presence before lecanemab, and a portfolio of consumer health products and older primary-care drugs in Japan and Asia. Eisai also runs a visible, long-standing neglected-tropical-disease program, notably donating diethylcarbamazine (DEC) tablets to the WHO for lymphatic filariasis elimination, which fits the 'hhc' framing and remains a recruiting talking point. Strategically the company is organized around two domains (Neurology and Oncology) plus a Consumer Healthcare segment, with Japan, Americas, EMEA, and Asia (China / APAC) as the regional pillars, and any candidate should read the most recent Integrated Report before interviewing because the domain-and-region matrix is how internal careers and P&Ls are actually structured.

Application Process

  1. 1
    Decide which legal entity you are actually applying to before you open any porta

    Decide which legal entity you are actually applying to before you open any portal: Eisai Co., Ltd. (the Japan-listed parent in Bunkyo, Tokyo) hires primarily through its Japanese-language recruitment site at eisai.co.jp/company/saiyo, while Eisai Inc. (the U.S. subsidiary headquartered in Nutley, New Jersey on the former Hoffmann-La Roche campus) runs a separate English-language careers site at us.eisai.com/careers, and Eisai Europe / Eisai Ltd. (Hatfield, UK and EU affiliates), Eisai China (Shanghai / Suzhou), and Eisai KR / TW / SEA operate their own regional hiring channels; a job on LinkedIn may sit in any of these legal entities with materially different compensation, employment law, and benefits.

  2. 2
    For Japanese new-graduate (shinsotsu / 新卒) hiring, register on the cohort-tagged

    For Japanese new-graduate (shinsotsu / 新卒) hiring, register on the cohort-tagged mypage on the Eisai recruiting portal in your junior or senior university year (or master's equivalent for research tracks); the company recruits via standard Japanese platforms including Mynavi (job.mynavi.jp), Rikunabi, and the Eisai-specific mypage, and follows the Keidanren-aligned calendar with setsumeikai (company briefings) from March, entry sheet and SPI3 aptitude testing in spring, multi-round interviews through early summer, and naitei (informal offers) typically issued in June of the penultimate year before graduation — significantly earlier than most U.S. pharma timelines.

  3. 3
    For Japanese mid-career (chuto saiyo / 中途採用) hiring, apply through the キャリア採用 se

    For Japanese mid-career (chuto saiyo / 中途採用) hiring, apply through the キャリア採用 section of the Eisai careers site or via executive-search firms and scout platforms (BizReach, JAC Recruitment, Robert Walters, Michael Page's pharma desk); mid-career hiring is strongly functional (medical affairs, global brand, regulatory, CMC, clinical development, data science, commercial analytics, HR, finance) rather than generalist rotation, and the funnel runs roughly 2-3 behavioral interviews plus a practical case or technical panel over 4-8 weeks.

  4. 4
    For Eisai Inc

    For Eisai Inc. (U.S., Nutley NJ) roles, apply through us.eisai.com/careers, which is an English-language site running a standard U.S. biotech/pharma recruiting process: online application, recruiter screen, hiring-manager interview, panel with 3-5 cross-functional interviewers (often mixed on-site at Nutley and video), and offer with standard U.S. pharma benefits; MSL, medical affairs, commercial, market access, and Leqembi launch roles have been the highest-volume Nutley openings in recent cycles.

  5. 5
    For Eisai EMEA roles in Hatfield (UK), Frankfurt, Milan, Madrid, or Paris, apply

    For Eisai EMEA roles in Hatfield (UK), Frankfurt, Milan, Madrid, or Paris, apply through the regional careers page (eisai.eu or eisai.co.uk/careers) with the local-language or English CV as appropriate; expect NHS-aware market-access framing for UK roles, and EMA/regulatory fluency for European regulatory and medical affairs tracks.

  6. 6
    For research and clinical-development roles, the two gravity centers are Tsukuba

    For research and clinical-development roles, the two gravity centers are Tsukuba (Japan) for the discovery and translational research functions historically associated with the Lenvima and lecanemab programs, and Andover (Massachusetts) and Cambridge (MA / Kendall Square ecosystem) for biologics and U.S. clinical development; candidates should target the specific site in their application because site culture and scientific focus differ materially.

  7. 7
    Expect a multi-round interview structure across all regions: after the initial r

    Expect a multi-round interview structure across all regions: after the initial recruiter screen, Japanese HQ candidates typically face the hiring manager, a senior leader in the function, a behavioral interview focused on 'hhc' alignment (how you think about patients, caregivers, and access), and a final executive-officer round; U.S. and EU candidates face a similar structure compressed into fewer calendar days and with stronger emphasis on functional deliverables and compliance fluency. Leqembi-related roles sometimes include a written case or scenario exercise about launch strategy, access, or MSL engagement.

Resume Tips for Eisai

recommended

Submit a Japanese-language rirekisho (履歴書) and shokumu keirekisho (職務経歴書) for an

Submit a Japanese-language rirekisho (履歴書) and shokumu keirekisho (職務経歴書) for any Japan-based role at the Bunkyo HQ, Tsukuba research center, or any Japanese commercial or plant site; English-only resumes are acceptable for Eisai Inc. (Nutley NJ), Eisai Europe (Hatfield), and designated global roles, but dual-language submissions strengthen global roles materially and are sometimes required for cross-regional HQ-liaison positions.

recommended

Lead with therapeutic-area expertise in neurology (Alzheimer's, epilepsy, insomn

Lead with therapeutic-area expertise in neurology (Alzheimer's, epilepsy, insomnia, neurodegeneration) or oncology (solid tumors, IO combinations, kinase inhibitors) rather than generic 'pharma' framing; Eisai explicitly organizes its pipeline around a Neurology domain and an Oncology domain, and recruiters screen resumes for TA fit before seniority fit. Candidates with dementia-care, biomarker (amyloid PET, CSF, plasma p-tau), or neuropsychiatric trial experience stand out for Leqembi-adjacent roles, while Keytruda-combination IO trial experience is the highest-signal background for Lenvima-adjacent roles.

recommended

For Medical Science Liaison (MSL), Medical Affairs, and field-medical roles, qua

For Medical Science Liaison (MSL), Medical Affairs, and field-medical roles, quantify KOL engagement (HCPs covered, advisory board participation, congress activity, publications supported) and name specific disease-state conferences (CTAD, AAIC, AAN, ASCO, ESMO, ASH) you have attended or presented at; MSL roles at Eisai are high-expectation positions with strong publication and congress responsibilities, and abstract vagueness is a quick disqualifier.

recommended

For Medical Representative (MR / 医薬情報担当者) roles in Japan, state your MR Certific

For Medical Representative (MR / 医薬情報担当者) roles in Japan, state your MR Certification status (MR認定証) prominently if you hold one, list your territory history and product portfolio at prior employers, and include your pharmacology or pharmacy-school background; if you are a pharmacist (薬剤師), put the license number on your rirekisho. New-graduate MR hiring usually does not require the certification up front because Eisai provides the training, but lateral MRs without it will not make the shortlist.

recommended

For research, biomarker, translational, and clinical pharmacology roles, foregro

For research, biomarker, translational, and clinical pharmacology roles, foreground publications (first-author and co-author), patents, and specific modalities (monoclonal antibodies, ADCs, small-molecule kinase inhibitors, neurodegenerative biomarkers, PK/PD modeling); Eisai prides itself on its in-house discovery track record (lenvatinib was a Tsukuba molecule) and expects research candidates to speak credibly about the science, not just the operations.

recommended

For commercial, market-access, and launch-excellence roles, lead with payer and

For commercial, market-access, and launch-excellence roles, lead with payer and access outcomes for neurology or oncology launches (specifically, Alzheimer's launch experience is gold dust right now given the Leqembi commercial ramp), and include country-level or regional P&L, forecasting, and cross-functional launch-readiness deliverables; Leqembi access work at the state Medicaid, CMS, IDN, and large infusion-network level is the single most transferable experience you can show for U.S. roles.

recommended

For global HQ roles where you will liaise between Tokyo, Nutley, and Hatfield, p

For global HQ roles where you will liaise between Tokyo, Nutley, and Hatfield, prove cross-cultural fluency with concrete examples (multi-region launches, global SOP harmonization, global steering committees) rather than soft language, and state clearly whether you are relocation-flexible; Eisai tenkin (転勤) culture at the Japan HQ is real but milder than at general trading houses or large manufacturers, and global HQ roles often expect periodic travel to at least two of the three gravity centers.

recommended

Show alignment with 'hhc' (human health care) genuinely and concretely: rather t

Show alignment with 'hhc' (human health care) genuinely and concretely: rather than quoting the phrase, cite patient-focused work you have actually done (patient-advocacy collaborations, caregiver research, lived-experience panels, patient-reported outcomes work, access-program design); interview panels test for this in behavioral rounds and hollow invocations of the phrase are a negative signal.

Interview Culture

Eisai interviews are recognizably Japanese-pharma in tone but with a distinctive 'hhc' flavor that candidates should understand before walking into the room.

At the Bunkyo Tokyo HQ, dress is conservative business formal (dark suit, white shirt, conservative tie for men; dark suit with neutral blouse for women), arrival should be 10-15 minutes early, printed copies of the rirekisho and shokumu keirekisho should be brought even when submitted online, and standard Japanese business etiquette applies: seat yourself only when directed, accept business cards (meishi) with both hands and place them on the table in interviewer order, and avoid interrupting even to correct a minor error. Panels typically run 2-3 rounds for mid-career candidates, starting with HR and the hiring manager, moving to functional peers and a senior director, and culminating in a general manager or executive officer for senior roles; new-graduate shinsotsu tracks include a group discussion (GD) round and SPI3 aptitude testing in addition to the interview sequence. Questions move predictably from motivations (shibo doki, specifically why Eisai rather than Takeda, Astellas, Daiichi Sankyo, Chugai, or a global top-ten) through factual understanding of the pipeline (what is your view of the Leqembi commercial ramp; how do you think about Alzheimer's diagnosis infrastructure; what is the rationale for the Lenvima-Keytruda combination strategy; how should Eisai think about its consumer-health segment) to behavioral questions about teamwork, patient focus, and ethical dilemmas. Factual grounding matters: candidates who have not read the latest integrated report, the Leqembi launch disclosures, or the recent IR day materials are usually visible within the first 15 minutes. The cultural specificity of Eisai interviews centers on the 'hhc' (human health care) philosophy and the 1% rule, both associated personally with CEO Haruo Naito. 'hhc' is not a marketing slogan inside the company; it is embedded in the articles of incorporation, the long-term mission statement, and the evaluation framework. Candidates will be asked how they think about patients, caregivers, and unmet need in concrete terms, and the strongest answers are specific (a caregiver story, a patient-advocacy interaction, a disease-state community you have spent time with) rather than abstract. The 1% rule expects every employee, regardless of function, to spend approximately 1% of working time in direct contact with patients, caregivers, or healthcare workers, and new hires are routinely asked how they would use that time and what they have already done in that spirit. Interviewers also probe long-termism: Eisai, under Naito-san, has been unusually willing to tolerate long R&D timelines and commercial setbacks in the pursuit of disease-modifying Alzheimer's therapy, and panels test whether candidates are comfortable inside that long-cycle mindset rather than chasing quarter-over-quarter wins. For mid-career candidates arriving from U.S. big-pharma, this is often the single biggest cultural calibration: the cadence of decision-making, the deference to HQ, and the comfort with three-to-five-year strategic arcs are real and should be accepted rather than challenged in the interview. Differences between the Japan HQ, Eisai Inc. (Nutley NJ), Andover MA research, and Hatfield UK cultures are meaningful and interviewers will probe whether you understand the one you are joining. The Bunkyo Tokyo HQ is the most traditional of the group, with formal Japanese corporate norms, strong consensus (nemawashi) decision-making, and deep institutional identification with the Naito family and the 1941 founding. Eisai Inc. at Nutley is operationally a U.S. biotech organization in tone, influenced by its Leqembi launch responsibilities, CMS and payer engagement, and MSL field force; decision-making is faster and more individual-contributor-oriented than in Tokyo, though major strategic decisions still escalate to Tokyo. Andover and Cambridge (MA) are scientific and research-culture organizations, closer to academic medicine than to Japanese corporate culture, and often recruit PhD and MD/PhD candidates directly from the Boston-Cambridge biotech ecosystem. Hatfield (UK) is a smaller, EMA-facing commercial and medical-affairs hub with NHS-aware market-access work and a pan-European regulatory orientation. Any candidate who treats 'Eisai' as a single monoculture misreads the company; the interview panel usually includes at least one person whose role is to confirm you understand which culture you are joining and can thrive there.

What Eisai Looks For

  • Authentic alignment with 'hhc' (human health care) demonstrated through concrete patient- and caregiver-focused work, not slogan repetition; Eisai panels test for this in every non-technical round and candidates who cannot speak to a real patient or caregiver interaction struggle to convert offers.
  • Deep therapeutic-area fluency in neurology (Alzheimer's, epilepsy, insomnia, broader neurodegeneration) or oncology (solid tumors, kinase inhibitors, IO combinations, thyroid and hepatocellular cancer specifically); generalist pharma backgrounds are welcome at entry and commercial levels but experienced hires are expected to own a TA.
  • Long-cycle patience and comfort with a 3-5 year strategic horizon rather than quarterly optimization; the Leqembi program ran for more than two decades from early BAN2401 work through FDA approval in 2023, and the company evaluates candidates for the temperament to tolerate long timelines and commercial ramps.
  • Japanese-language capability at JLPT N2 or higher for any HQ or Japan-based role outside designated English-language global positions; N1 is the practical bar for HQ R&D planning, corporate strategy, IR, and legal functions where Japanese is the daily operating language, and for global HQ roles that liaise with regional affiliates in Japanese.
  • Cross-cultural effectiveness between Japan, the U.S., and the EU, ideally demonstrated through multi-region launches, global development programs, or global SOP harmonization work; Eisai's Neurology and Oncology domains are run globally and candidates who have never operated across the Pacific are at a structural disadvantage for senior roles.
  • Scientific credibility, even outside research roles, measured by the ability to speak coherently about the pipeline (Leqembi's subcutaneous maintenance formulation, the tau antibody E2814 program, Lenvima's combination strategy with Keytruda, the rationale for new neurology indications); Eisai leaders are scientifically literate and expect the same from commercial, access, and corporate hires.
  • Stewardship, humility, and team framing in tone; flashy self-promotion lands poorly, and candidates who credit teams and cite specific collaborators are read as culturally fit, while those who over-claim individual heroics are read as misaligned with the cooperative norms of Japanese pharma.
  • Ethical seriousness and pharmacovigilance fluency, particularly for any role touching ARIA monitoring, Alzheimer's patient safety, or oncology combination trials; Eisai takes post-marketing surveillance and real-world safety profiles of Leqembi seriously and expects candidates to do the same.

Frequently Asked Questions

What is the typical starting salary for a new-graduate role at Eisai Co., Ltd. in Japan?
Eisai Japan shinsotsu starting compensation for university graduates entering generalist or MR tracks is typically 230,000-260,000 JPY per month as base salary, with a bi-annual bonus that brings year-one annual cash compensation into roughly the 4.5-6 million JPY band. Master's graduates entering R&D, clinical development, or regulatory tracks start higher, often in the 6-7 million JPY year-one band, and PhD hires entering the Tsukuba research center can reach the 7-9 million JPY band in year one depending on specialization. These figures are broadly competitive with Astellas and Daiichi Sankyo at the new-graduate level, slightly below Takeda's Japan bands, and materially below Chugai (which pays closer to its Roche parent's European bands). Promotion-track progression at Eisai is generally slower than at Takeda or Chugai but faster than at more traditional peers.
How does compensation at Eisai Inc. (Nutley, NJ) compare to the Tokyo HQ?
Eisai Inc. in Nutley, New Jersey runs on U.S. biotech and pharma compensation bands and is not pegged to Tokyo. Entry-level commercial and medical affairs roles typically start in the 90,000-130,000 USD base range with standard U.S. biotech benefits and bonus, MSL roles typically land in the 150,000-200,000 USD total-cash range depending on experience and therapeutic area, senior medical affairs, market access, and launch-leadership roles reach the 200,000-350,000 USD total-cash range, and director-and-above levels are competitive with mid-size U.S. biotech peers on the Nutley-Jersey City-New York corridor. Nutley candidates should evaluate their offers against Regeneron, Bristol-Myers Squibb, Novartis U.S., and mid-cap neurology biotechs, not against Tokyo HQ bands. Relocation between Nutley and Tokyo is rare and usually structured as an expat assignment rather than a local-to-local move.
What happens if I receive a better offer from Takeda, Astellas, Daiichi Sankyo, or Chugai?
This is the single most common outcome Eisai recruiting loses on, and it is worth understanding candidly. Takeda pays more at senior levels and offers broader global rotation; Astellas and Daiichi Sankyo are similarly sized and often perceived as closer peers with comparable pay; Chugai's de facto alignment with Roche means its bands track European big-pharma pay and its brand prestige within Japan is near the top. Eisai's honest pitch is not 'we pay the most' but 'we are the Japanese pharma most identified with CNS and disease-modifying Alzheimer's therapy, we have the longest-tenured CEO in the industry, and we operate on a genuinely long-cycle mission framing.' If neurology and patient-centricity matter more than absolute prestige, Eisai converts well; candidates optimizing for brand or pay typically take competing offers.
Is CEO Haruo Naito's long tenure a concern? What is the succession plan?
Candid answer: Naito-san has led Eisai since 1988, making his tenure more than 36 years as of early 2026, and succession is a legitimate governance topic that thoughtful candidates should raise internally and expect to be asked about. The company's public disclosures have included senior-officer appointments that are widely read as building a successor bench, and the 'hhc' philosophy is institutionalized well enough that it does not depend on one person. That said, the Naito family association with the company is genuine and historical (Naito-san is the grandson of founder Toyoji Naito), and a post-Naito transition will mark a real cultural inflection. Candidates who want long-term career stability should interview senior leaders about succession philosophy, talent development, and the next-five-year leadership pipeline; those conversations are welcomed rather than penalized and often signal seriousness about long tenure.
How real is the Leqembi commercial ramp versus the early expectations?
The commercial reality is more measured than the January 2023 approval headlines suggested, and an honest answer helps in interviews more than cheerleading. Leqembi launch depends on Alzheimer's diagnostic infrastructure that is still being built: amyloid PET capacity, CSF testing availability, plasma-biomarker validation, APOE genotyping workflows, infusion-center throughput, and MRI monitoring for ARIA (amyloid-related imaging abnormalities). Revenue has grown meaningfully quarter over quarter since launch but has not reached the multi-billion-USD run rate that aggressive early analyst models assumed, and CMS coverage, state-Medicaid coverage in the U.S., and pricing negotiations in Europe and Japan each have their own timelines. The 2025 subcutaneous maintenance approval extends the franchise and reduces infusion-chair friction. For candidates, the implication is that Leqembi-adjacent roles are absolutely high-leverage and career-defining, but also that the work is real launch-infrastructure work rather than a presumed cash-machine role, and the company's tolerance for a long ramp is cultural.
What are the MR (医薬情報担当者 / medical representative) career prospects at Eisai Japan?
Eisai is one of the major MR employers in Japan, historically oriented around the Aricept franchise and now increasingly around Leqembi specialty-care MRs and the oncology franchise supporting Lenvima with MSD. New-graduate MR hiring does not require pre-existing MR Certification (MR認定証) because the company provides the three-part structured training program and supports employees through the certification exam in their first 12-18 months; candidates with pharmacy-school or pharmacology backgrounds have an edge. Career progression runs from MR to senior MR to area manager to branch manager to marketing or training HQ roles over 8-15 years. MR compensation is roughly 4.5-7 million JPY in the first 3-5 years and can reach 9-12 million JPY at senior area-manager levels; Leqembi specialty MRs, because of the narrower HCP targeting and the biomarker-diagnosis ecosystem work, are a higher-prestige internal track than generalist MR roles.
What is the 'hhc' (human health care) philosophy and why does it matter in interviews?
The 'hhc' (human health care) philosophy is Eisai's mission framing, formally introduced in 1992 under CEO Haruo Naito, written into the articles of incorporation, and operationalized through the so-called '1% rule' that expects every employee to spend approximately 1% of working time in direct contact with patients, caregivers, and healthcare workers, regardless of function. It is genuinely embedded in the evaluation framework, and candidates who treat it as a slogan rather than a practice are usually detected quickly. In interviews, the strongest approach is to describe specific patient or caregiver interactions you have already had, explain what you learned from them, and outline how you would use the 1% time at Eisai concretely (advocacy group collaboration, dementia-caregiver shadowing, patient-panel participation, clinical-site time). Abstract invocations of 'patient-centricity' without concrete examples are a common disqualifier.
How much Japanese do I need to work at Eisai Japan versus Eisai Inc. in Nutley?
For any Japan-based role at the Bunkyo HQ, Tsukuba research center, or Japanese plants, practical Japanese at JLPT N2 or higher is a floor and N1 is the de facto bar for HQ R&D planning, corporate strategy, IR, legal, and senior management roles because internal meetings, documents, and decision-making run in Japanese. Designated English-language global tracks exist for specific R&D and regulatory positions but they are a minority. For Eisai Inc. in Nutley NJ, Japanese is not required for the vast majority of roles; the site operates in English and interacts with Tokyo through bilingual liaisons and scheduled global meetings. Japanese capability is a real differentiator for roles with a global-HQ interface dimension (global brand, global medical affairs, global regulatory), and candidates with Japanese plus a strong U.S. biotech track record have been particularly well-represented in senior Leqembi launch and global-brand roles.
What ATS or recruiting platforms does Eisai use and how are applications evaluated?
Eisai Co., Ltd. in Japan runs its new-graduate hiring through a cohort-tagged mypage integrated with Mynavi (job.mynavi.jp), Rikunabi, and the company's own careers site at eisai.co.jp, supplemented by SPI3 aptitude testing delivered through the standard third-party provider; mid-career applications in Japan go through the キャリア採用 section of the careers site and through external scout platforms (BizReach, JAC Recruitment, Michael Page, Robert Walters pharma desk). Eisai Inc. in Nutley uses a standard U.S. pharma ATS (historically Workday-based) accessed through us.eisai.com/careers. Eisai Europe at Hatfield runs a UK/EU-compliant applicant flow through eisai.eu and local regional sites. ATS evaluation is keyword-sensitive for mid-career postings, particularly for therapeutic-area terms (Alzheimer's, Leqembi, amyloid, ARIA, lecanemab, Lenvima, lenvatinib, KEYNOTE combinations, MSL, market access) and for Japanese-language capability markers (JLPT N1/N2, rirekisho, 薬剤師 license, MR認定). Submitting a rirekisho and shokumu keirekisho in addition to an English CV for Japan-based roles materially improves downstream evaluation.
What about Eisai's neglected-tropical-disease (NTD) work and the DEC donation program?
Eisai's long-running donation of diethylcarbamazine (DEC) tablets to the World Health Organization for the elimination of lymphatic filariasis is a genuine and long-standing program rather than a talking-point CSR initiative; the company has supplied billions of tablets over more than a decade and the program is referenced regularly in leadership communications and the Integrated Report as a concrete expression of the 'hhc' mission. For candidates, this matters in two ways: (1) it is a legitimate interview topic, particularly for global-health, access, regulatory, and medical-affairs roles, and demonstrating familiarity with the program's history and current status is a low-cost way to signal preparation, and (2) a small number of roles, especially in global access and WHO-facing regulatory functions, touch the NTD program directly. Candidates with global-health, WHO, PAHO, or LMIC regulatory experience and a genuine interest in access-to-medicines work can use this thread as a credible differentiator.

Open Positions

Eisai currently has 87 open positions.

Check Your Resume Before Applying → View 87 open positions at Eisai

Related Resources

Similar Companies

Related Articles

Sources

  1. Eisai Co., Ltd. Corporate Website (Japanese HQ) —
  2. Eisai Japan Recruitment Site (shinsotsu / chuto saiyo) —
  3. Eisai Inc. U.S. Careers (Nutley, NJ) —
  4. Eisai Co., Ltd. Integrated Report (Investor Relations) —
  5. FDA Approval of Leqembi (lecanemab) for Alzheimer's Disease —
  6. Eisai-Biogen Lecanemab Collaboration Disclosures —
  7. Eisai-Merck Lenvima Strategic Collaboration (2018) —
  8. Tokyo Stock Exchange Listing (Eisai 4523) —